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Semaphorin3a was discovered as a secreted guidance protein
that acts as a chemorepellent to migrating axons and
endothelial cells. In the adult mouse kidney, it is expressed
in podocytes and collecting tubules. Here, we show that
exogenous semaphorin3a caused acute nephrotic range
proteinuria associated with podocyte foot process
effacement and fusion, endothelial cell damage, decreased
vascular endothelial growth factor-A receptor expression,
and downregulation of the slit-diaphragm proteins podocin,
nephrin, and CD2-associated protein. When vascular
endothelial growth factor 165 was administered at the same
time as Semaphorin3a, no proteinuria or renal ultrastructural
abnormalities occurred, suggesting that semaphorin3a
effects may be mediated, in part, by downregulation of
vascular endothelial growth factor receptor 2 signaling. Our
findings indicate that a balance of semaphorin3a to vascular
endothelial growth factor-A may be important for glomerular
filtration barrier homeostasis.
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Class 3 semaphorins are a family of secreted guidance
proteins.1,2 Semaphorin3a (Sema3a) plays an important role
in neural and cardiovascular patterning.3 Sema3a generates
chemorepellent cues by inducing growth cone collapse and
inhibiting endothelial and neural crest cell migration.4–7
Semaphorin3a (SEMA3A) binds to neuropilins 1 and 2, also
known as co-receptors for the vascular endothelial growth
factor-A (VEGF-A) isoform VEGF165, and signals through
plexins A13 and D1.
4,8,9 SEMA3A signaling decreases
integrin function and interferes with the actin cytoskele-
ton.7,10,11 Semaphorins and their receptors have been
detected in endothelial cells, neurons, podocytes, and tubular
epithelial cells in vivo and in vitro.10,12–16
Deletion of the Sema3a gene in mice causes perinatal
lethality associated with atrial dilatation, septum defects, and
vascular patterning abnormalities.10,17 Plexin D1 disruption
in mice and zebrafish induces cardiovascular malformations
consistent with Sema3a, Sema3c, and VEGF165 null pheno-
types, suggesting that class 3 semaphorins and VEGF-A have
coordinated functions in cardiovascular patterning.3,12,13
SEMA3A expression in the kidney is developmentally
regulated. Initially detected in all epithelial cells, Sema3a
mRNA transcripts localize to podocytes and collecting
tubules in the mature organ.15 In cultured podocytes,
SEMA3A signaling regulates the expression and interactions
of slit-diaphragm proteins and decreases podocyte survival.16
However, the function of SEMA3A in vivo remains unknown.
We hypothesized that SEMA3A counterbalances VEGF-A
functions in the podocyte and that together they regulate slit-
diaphragm homeostasis. Hence, excess or lack of either
protein could cause glomerular filtration barrier permeability
abnormalities and proteinuria. Excess and neutralization of
VEGF-A have been shown to result in proteinuria.18–23 The
potential role of SEMA3A in the pathogenesis of proteinuria
has not been explored. Here, we asked whether excess
circulating SEMA3A causes proteinuria and renal damage.
We report that remarkably, systemic SEMA3A injection into
healthy mice causes acute and transient massive proteinuria,
podocyte foot process effacement, endothelial cell damage,
and downregulation of slit-diaphragm proteins as well as
downregulation of the signaling VEGF-A receptor 2
(VEGFR2). These abnormalities are abrogated by co-adminis-
tration of SEMA3A and VEGF-A.
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RESULTS
To examine the effect of systemic SEMA3A on glomerular
filtration barrier function, we infused recombinant SEMA3A
intraperitoneally in adult healthy mice. SEMA3A adminis-
tration induced nephrotic range proteinuria within 4 h,
whereas injection of denatured SEMA3A, vehicle, or an
irrelevant protein did not do so (Figure 1a). SEMA3A-
induced proteinuria resolved by 24 h (Figure 1a). At the end
of the experiment (4–48 h), kidneys were harvested, pro-
cessed, and examined by light and electron microscopy. No
histological abnormalities were detected by light microscopy
in SEMA3A-treated or control kidneys (data not shown).
Kidneys from mice injected with vehicle or denatured
SEMA3A (controls) were indistinguishable and showed
normal podocyte, glomerular basement membrane, and
endothelial cell ultrastructure (Figure 1b and c). Transmis-
sion electron microscopy revealed extensive fusion and
effacement of podocyte foot processes in all kidneys
examined 4 h after SEMA3A infusion (Figure 1d–g). In the
fused foot processes, slit diaphragms were replaced by
occludens junction-like structures (Figure 1f). Patchy similar
lesions were observed in most of the mice (4/5) examined at
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Figure 1 | SEMA3A induced massive transient proteinuria via podocyte foot process effacement and fusion and endothelial cell
damage. (a) Quantification of proteinuria 4 and 24 h after SEMA3A, vehicle, or denatured sema 3A injection (control); data are expressed as
meanþ s.e.m. Albumin:creatinine ratio in the urine. (b–j) Transmission electron microscopy images: (b) control kidney 4 h after vehicle injection
showing normal foot processes separated by slit diaphragms (black triangles), normal GBM, and an endothelial cell with normal fenestrations
(black arrows); (c) control kidney showing two foot processes linked by a slit diaphragm at higher magnification. (d–g) SEMA3A-treated kidneys
4 h after SEMA3A injection: (d) effacement and fusion of foot processes (red triangles), endothelial cell swelling, and lack of fenestrations
(single-ended red arrows); (e) extensive foot process effacement and fusion (red triangles); (f) an occluding junction between adjacent
podocytes instead of the slit diaphgram; and (g) endothelial cell detachment (red arrows and black dotted line), vacuoles and damage, and
podocyte foot process fusion (red triangles); (h) SEMA3A-treated kidney 24 h after injection showing patchy podocyte lesions (red and black
triangles) and normal endothelial fenestrations (black arrows); (i and j) SEMA3A-treated kidney 48 h after injection shows normal podocyte and
endothelial cell ultrastructure; (j) intact slit diaphragms (black triangles) and fenestrae (black arrows) at higher magnification. Note that the
glomerular basement membrane (GBM) remains intact throughout. Bar¼ 200 nm.
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24 h (Figure 1h). Glomerular endothelial cell swelling, lack of
fenestrations, and damage, as indicated by vacuoles and
partial detachment, were observed 4 h after sema 3A infusion
(Figure 1d and g). The glomerular basement membrane did
not show significant changes at any time point examined.
Podocyte and endothelial cell lesions resolved completely at
48 h (Figure 1i and j).
To begin to elucidate the molecular basis of sema 3A-
induced abnormalities, we examined the expression level and
distribution of the slit-diaphragm proteins podocin, CD2AP,
and nephrin in control and SEMA3A-treated mice by western
blot analysis and immunocytochemistry. To enrich the
kidney lysates for podocyte proteins, we used isolated
glomeruli. SEMA3A induced a significant decrease in CD2AP,
podocin, and in the nephrin protein level 4 h post-injection
(Figure 2a–c). These changes were transient and resolved by
24–48 h, as did the proteinuria and the ultrastructural
abnormalities (Figure 1). SEMA3A did not alter the
localization of podocin, nephrin, and CD2AP to podocytes,
and it did not change the localization of synaptopodin, a
prototypical marker of differentiated podocytes (Figure 2d).
Next, we asked whether systemic SEMA3A regulates renal/
glomerular VEGF-A and VEGFR2 expression. We determined
that SEMA3A does not alter VEGF-A protein level (Figure 3a),
but rather induces a significant decrease in VEGFR2 kidney
protein level in SEMA3A-treated mice as compared to control
mice (Figure 3b), suggesting that SEMA3A effects may be
mediated, in part, by downregulation of VEGFR2 signaling.
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Figure 2 | SEMA3A induces downregulation of CD2AP, podocin, and nephrin. Proteins from X4 mouse kidneys were pooled before
SDS-PAGE in all conditions. (a) Left: western blot showing decreased CD2AP level after SEMA3A injection and right: quantification of
densitometric changes as compared to control, after correction for actin (loading control). Data are expressed as meanþ s.e.m., n¼ 5, *Po0.05.
(b) Western blot showing decreased podocin level after SEMA3A injection, quantification as described in (a), n¼ 5. (c) Western blot showing
decreased nephrin expression level after SEMA3A injection, quantification as described in (a), n¼ 4; actin expression levels were used to
normalize for protein loading. (d) Fluorescence immunohistochemistry showing localization of CD2AP, podocin, nephrin, and synaptopodin
to podocytes in control and SEMA3A-treated kidney sections, original magnification  600.
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To gain insight into SEMA3A/VEGF-A interactions, we
used an immortalized mouse podocyte cell line24 expressing
both ligands and their receptors.16,25 We determined that
SEMA3A induces a decrease in VEGFR2 mRNA (Figure 3c)
and VEGFR2 protein level, whereas addition of VEGF165 in
equimolar concentration prevents these changes (Figure 3d),
supporting a role for SEMA3A/VEGF-A balance in podocyte
signaling.
Next, we investigated whether co-administration of equi-
molar doses of SEMA3A and VEGF165 can prevent protein-
uria or glomerular filtration barrier damage induced by
SEMA3A in vivo. We determined that SEMA3AþVEGF165-
treated mice did not develop acute proteinuria (Figure 4a).
Transmission electron microscopy showed a normal glome-
rular ultrastructure in SEMA3AþVEGF165-treated mice
(Figure 4b). Accordingly, nephrin, podocin, and VEGFR2
expression levels were normal in SEMA3AþVEGF165-treated
mice (Figure 4c and d). Collectively, these findings suggest
that VEGF165 competition for neuropilin 1 binding prevents
SEMA3A signaling and abrogates SEMA3A-induced podo-
cyte and endothelial cell damage.
In summary, our results indicate that SEMA3A causes
acute proteinuria, associated with reversible podocyte and
endothelial cell damage, which are prevented by VEGF165,
suggesting that SEMA3A/VEGF-A balance is involved in
glomerular filtration barrier homeostasis.
DISCUSSION
This study demonstrates that excess circulating SEMA3A
causes acute proteinuria associated with podocyte foot
process effacement and fusion, as well as endothelial cell
damage and downregulation of slit-diaphragm proteins and
VEGFR2. Both the podocyte ultrastructural abnormalities
and the increased permeability of the glomerular filtration
barrier are transient and reversible. To rule out nonspecific
effects triggered by a heterologous protein, we injected
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Figure 3 | SEMA3A decreases VEGFR2 expression in vivo and in
cultured podocytes. (a) Representative western blot showing
that VEGF164 expression is not altered by SEMA3A, actin¼ loading
control. (b) Representative western blot showing that SEMA3A
downregulates VEGFR2 expression, actin¼ loading control;
quantification in (a and b) as described in Figure 2a, n¼ 4; proteins
from X4 mouse kidneys were pooled before SDS-PAGE in all
conditions. (c) RT-PCR amplification showing that SEMA3A decreases
VEGFR2 mRNA, optical density corrected for GAPDH, and expressed
as meanþ s.e.m., n¼ 4, *Po0.05. (d) Western blot from podocyte
whole-cell lysate showing SEMA3A-induced VEGFR2 downregulation,
which is abrogated by VEGF165, actin¼ loading control.
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Figure 4 | VEGF165 abrogates SEMA3A effects on glomerular permeability, ultrastructure, and gene expression in vivo. (a)
Albumin:creatinine ratio in the urine 4 h after SEMA3A (3A), SEMA3AþVEGF165 injection (3AþV), or vehicle (con), data are expressed as
meanþ s.e.m. (b) TEM of a SEMA3AþVEGF165-treated kidney showing normal glomerular ultrastructure, inset shows intact slit diaphragms,
GBM, and endothelial cell fenestrations at higher magnification, bar¼ 500 nm. (c) Western blots showing that nephrin and podocin protein
levels in SEMA3AþVEGF165-treated kidneys are not different from controls, whereas both proteins decrease in SEMA3A-treated kidneys,
actin¼ loading control. (d) Western blot showing that VEGFR2 protein level in SEMA3AþVEGF165-treated kidneys is not different from controls,
whereas VEGFR2 decreases in SEMA3A-treated kidneys and increases in VEGF165-treated kidneys, actin¼ loading control. Proteins from X3
mouse kidneys were pooled before SDS-PAGE in all conditions.
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denatured SEMA3A or collagen I and we confirmed that
neither of them induced proteinuria or renal ultrastructural
abnormalities, arguing that the effect of the intact SEMA3A
was specific and induced by signaling.
SEMA3A is known to control endothelial cell migration
and axon pathfinding by inducing rearrangements of the
actin cytoskeleton and decreasing integrin activity.7,10 We
have previously shown that the Sema3a gene is expressed in
podocytes throughout life,15 and that cultured podocytes
express Sema3a and its receptors neuropilin 1, 2, and plexins
A1–3 and D1.16 Podocyte exposure to recombinant SEMA3A
induced apoptosis, downregulation of podocin expression,
and decreased interactions between podocin/CD2AP and
podocin/nephrin in vitro.16 These studies suggested that sema
3A regulates the function of the slit-diaphragm signaling
complex and thus could alter the permeability of the
glomerular filtration barrier in vivo.
The results reported here show that a single injection of
recombinant SEMA3A causes transient massive proteinuria,
foot process effacement and fusion, and endothelial damage.
These changes were observed 4 h after SEMA3A infusion and
resolved within 48 h. Interestingly, the slit diaphragms were
replaced by ladder-like structures similar to occluding
junctions, such as those described during podocyte differ-
entiation at the capillary loop stage of glomerulogenesis,26,27
suggesting that foot process fusion may be a dynamic de-
differentiation process.26 Similar rapid changes have been
described following protamine sulfate infusion, where foot
process effacement involved nephrin phosphorylation and
was reversed by heparin.28,29 Replacement of slit diaphragms
by occluding junctions have also been observed in amino-
nucleoside nephrosis, in congenital nephrotic syndrome of
the Finnish type, and in minimal change disease, consistently
associated with transient or permanent proteinuria.27,30,31
To begin to elucidate the molecular basis of the
proteinuria and the ultrastructural changes induced by in
vivo SEMA3A infusion, we examined the expression of slit-
diaphragm proteins. We found that SEMA3A acutely and
transiently decreased podocin, CD2AP, and nephrin protein
levels, consistent with disregulating the slit-diaphragm
signaling complex. The mechanism(s) of SEMA3A-induced
podocin, CD2AP, and nephrin downregulation are unknown
and need to be explored. Although the mRNA and protein
half-life for these molecules has not been determined, given
the observed changes in 4 h, it is likely that the reduction in
protein levels involves protein degradation rather than
transcriptional or translational regulation. We cannot exclude
the possibility of SEMA3A-induced changes in post-transla-
tional modifications, such as nephrin phosphorylation, that
in turn may alter its signaling and protein interactions.29,32
The recovery of podocin, CD2AP, and nephrin protein levels
lagged behind the resolution of the proteinuria and the
improvement of the ultrastructural changes, suggesting that
there are additional, unidentified molecules involved in these
processes. The localization of slit-diaphragm proteins to
podocytes was not altered by SEMA3A. Podocin localizes to
the podocyte foot process cell membrane and physically
associates with CD2AP and nephrin.33,34 Disruption of the
podocin gene results in massive proteinuria, mesangial
sclerosis, and renal failure in mice.35 Downregulation of
podocin has been reported in the puromycin aminonucleo-
side nephrotic syndrome model and in LMX1B-mutant
mice.36,37 Podocin mutations in humans cause autosomal-
recessive familial focal glomerulosclerosis.38 CD2AP is an
adapter protein that interacts with podocin and nephrin and
anchors them to the actin cytoskeleton.34,39 CD2AP mutation
results in massive proteinuria and foot process effacement,
progressive glomerulosclerosis, and renal failure in mice.40 In
humans, CD2AP haploinsufficiency is associated with
proteinuric disease.41 Nephrin is an integral component of
the slit diaphragm that functions as an adhesion, a scaffold
and a signaling molecule.33 Nephrin mutations cause
congenital nephrotic syndrome of the Finnish type in
humans and massive proteinuria, lack of slit diaphragms,
and foot process fusion in mice.42,43 In view of the known
functions of these proteins,44 the functional and ultrastruc-
tural changes induced by SEMA3A strongly suggest that
downregulation of podocin, CD2AP, and nephrin played a
mechanistic role in the glomerular filtration barrier permea-
bility changes and ultrastructural abnormalities observed.
SEMA3A and VEGF165 compete for binding to neuro-
pilin 1 and have multiple opposite effects on endothelial cells,
neurons, and podocytes.7,16,45 Interestingly, both proteins
colocalize in podocytes.15,16,25,46 We propose a model where a
dynamic counterbalance between SEMA3A and VEGF-A
functions regulates the homeostasis of the slit-diaphragm
proteins and thus the permeability of the glomerular
filtration barrier. Several lines of evidence from in vivo and
in vitro studies support this hypothesis. Elegant experiments
showed transient proteinuria associated with ultrastructural
changes in mice injected with anti-VEGF antibody or soluble
flt-1 receptor.22 Similar abnormalities have been observed in
cancer patients treated with anti-VEGF antibody and in
women with preeclampsia.19,23,47 These studies proved that
neutralization of circulating VEGF-A (or excess ‘decoy’
receptor, soluble flt-1) induced nephrin downregulation
and suggested that podocyte VEGF-A signaling is necessary
to maintain the normal function and structure of the
glomerular filtration barrier. Here, we demonstrate that
excessive circulating SEMA3A induces downregulation of
podocin, CD2AP, and nephrin and results in similar
functional consequences, that is, increased permeability of
the glomerular filtration barrier and ensuing proteinuria. In
addition, we show that SEMA3A induces downregulation of
VEGFR2 without altering the VEGF-A kidney protein level in
vivo, suggestive of another mechanism decreasing VEGF-A
signals.
The in vivo results reported here are consistent with our
previous in vitro data showing that VEGF-A increases
podocin expression and its association with CD2AP, whereas
SEMA3A has the opposite effect, that is downregulation of
podocin and its interactions with CD2AP and nephrin.16,25
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VEGF-A and SEMA3A also have opposite effects on podocyte
survival: VEGF-A is a podocyte survival factor whereas
SEMA3A induces podocyte apoptosis in vitro.16,25,48 We also
showed that VEGF-A induces VEGFR2 upregulation in
cultured podocytes.25 In this study, we confirmed and
extended these in vitro findings, showing that SEMA3A
induces downregulation of podocyte VEGFR2 mRNA and
protein, and that addition of VEGF165 abrogates these
changes, supporting the notion that SEMA3A effects are
mediated, at least in part, by downregulation of VEGFR2
signaling. Moreover, we demonstrated that co-administration
of SEMA3A and VEGF165 in vivo abrogates the glomerular
ultrastructural abnormalities induced by SEMA3A, prevents
the development of proteinuria, and the downregulation
of slit-diaphragm proteins and VEGFR2. These results
imply that VEGF165 competes with SEMA3A for neuropi-
lin 1 signaling and restores glomerular filtration barrier
homeostasis.
In summary, we report a novel mechanism of proteinuria
induced by SEMA3A in mice. The physiologic levels and the
role of SEMA3A in proteinuric states are unknown. However,
the finding that excessive SEMA3A causes acute proteinuria
by disregulating slit-diaphragm proteins and VEGFR2
signaling may be important to uncover pathogenic mechan-
isms of proteinuric diseases, and may have potential
therapeutic implications, such as neutralization of SEMA3A
to prevent or decrease podocyte apoptosis and support slit-
diaphragm protein expression.
MATERIALS AND METHODS
Recombinant SEMA3A
As previously described,16 rat Sema3a cDNA (NM_017310) was
cloned into the EcoRI/NotI sites of the pHis.parallel vector.49
Escherichia coli BL21 DE3 Codon Plus (Stratagene, La Jolla, CA,
USA) were transformed with pHis.parallel/Sema3a and induced to
produce the recombinant protein with 1 mM IPTG (isopropyl-beta-
D-thiogalactopyranoside). SEMA3A was extracted from inclusion
bodies under denaturing conditions, refolded with a reducing buffer
followed by an oxidation buffer, dialyzed against decreasing urea
concentrations (2 M–7 mM) and concentrated using Amicon Ultra
filters (Millipore, Billerica, MA, USA).
SEMA3A injection and evaluation of proteinuria
Swiss-Webster 6-week-old male mice (n¼ 28) were given a single
sema 3A intraperitoneal injection (0.5 mg per g body weight),
SEMA3AþVEGF165 (0.15 mg per g body weight, Emolar dose,
n¼ 3) or VEGF165 (0.15 mg per g body weight, n¼ 3). Weight-
matched controls received a single intraperitoneal bolus of
denatured SEMA3A (n¼ 4) or an irrelevant protein (rat collagen I
0.5mg per g body weight, n¼ 4) or 0.5 ml vehicle (100 mM NaCl,
50 mM Tris-Cl, 192 mM glycine, 7 mM urea, and pH 7.5), (n¼ 20).
Four and 24 h after the intraperitoneal injection, mice were
anesthetized according to the National Institutes of Health Guide
for the Care and Use of Laboratory Animals. Urine was collected by
bladder puncture and kidneys were harvested. Urinary albumin and
creatinine concentrations were determined by enzyme-linked
immunosorbent assay (Albuwell M Elisa kit; Exocell, Philadelphia,
PA, USA) and colorimetric assay (creatinine colorimetric assay;
Oxford Biomedical Research, Oxford, MI, USA). Urine albumin
excretion was estimated as albumin:creatinine ratio.
Transmission electron microscopy
Kidneys were fixed in 2% paraformaldehydeþ 2.5% glutaraldehyde
in 0.1 M sodium cacodylate buffer, postfixed with 1% osmium
tetroxide followed by 1% uranyl acetate, dehydrated, and embedded
in LX112 resin (LADD Research Industries, Williston, VT, USA).
Ultrathin (80 nm) sections were cut (Reichert, Heidelberg, Germany,
Ultracut UCT), stained with uranyl acetate/lead citrate, and
examined by transmission electron microscopy (JEOL 1200EX).
Mouse glomerular isolation and western analysis
Mice previously treated for indicated time periods with vehicle,
SEMA3A, SEMA3AþVEGF165, or VEGF165 were anesthetized as
described above, and perfused with magnetic beads/PBS via left
ventricle puncture (Dynabeads; Dynal Corp, Oslo, Norway).
Kidneys were harvested and glomeruli were isolated using a
magnet.50 Glomeruli (average purity B85%) were lysed in RIPA
bufferþ protease inhibitors (Roche, Indianapolis, IN, USA)þ 1 mM
Na orthovanadateþ 1 mM NaF. Protein concentration was deter-
mined by bicinchoninic acid assay (Sigma, St Louis, MO, USA).
A total of 50–100 mg protein per lane were resolved in 6–15% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis. Polyclonal
primary antibodies used for immunoblotting were anti-podocin
(Podo 11A; Alpha Diagnostics Inc., San Antonio, TX, USA);
anti-CD2AP (no. sc-9137; Santa Cruz Technology, Santa Cruz,
CA, USA); anti-nephrin (Nephr 11A; Alpha Diagnostics); anti-
VEGF-A (no. sc-507; Santa Cruz Technology); anti-VEGFR2 (no.
sc-315; Santa Cruz Technology). Anti-actin (no. A2066; Sigma) was
used as a control for protein loading. Secondary antibodies used
were anti-rabbit or anti-mouse HRP-IgG (Amersham, Piscataway,
NJ, USA). Signals were visualized by enhanced chemoluminescence
(Amersham).
Immunohistochemical studies
Kidneys were embedded in optical coherence tomography (Sakura,
Torrance, CA, USA), snap-frozen in dry ice/isopentane and kept at
80 1C. Six micrometer cryosections were air dried, fixed in cold
acetone for 5 min, permeabilized with 0.3% TritonX-100, washed,
and exposed to blocking serum for 30 min. Sections were incubated
with the following primary antibodies for 2 h: anti-nephrin
(NPHN11-A; Alpha Diagnostic Inc.), anti-podocin (Podo 11-A;
Alpha Diagnostic Inc.), anti-CD2AP (no. sc-9137, Santa Cruz), and
anti-synaptopodin (clone G1D4, Biodesign International). Follow-
ing appropriate washes, sections were incubated with Cy2- or Cy3-
labeled secondary antibodies (Jackson ImmunoResearch, West
Grove, PA, USA) for 45 min, washed with PBS, and mounted
(Vectashield; Vector Laboratories, Burlingame, CA, USA). All
sections were examined by confocal microscopy (FV300; Olympus,
Center Valley, PA, USA) and images were taken at  60
magnification.
Cell culture
A conditionally immortalized mouse podocyte cell line was
maintained in RPMI 1640þ 10% fetal bovine serum as described
previously.16,24 Differentiated podocytes were serum starved for 4 h
and then exposed to serum-free media, serum-free mediaþ
recombinant sema 3A (50 ng ml1), serum-free mediaþVEGF165
20 ng ml1, or serum-free mediaþ sema 3A 50 ng ml1þVEGF165
20 ng ml1 for 4 h as indicated. At the end of the experiments,
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podocytes were lysed and processed for western analysis as described
above.
Statistical analysis
All experiments were performed X3 times. Glomeruli from four
mice in each experimental condition were pooled, proteins were
extracted for immunoblotting. Densitometric analysis of reverse
transcription-PCR and western blotting were performed, optical
density was corrected for protein loading and expressed as a
proportion of control signals (mean±s.e.m.). In all experiments,
control and experimental conditions were compared using t-test or
analysis of variance, as appropriate. Po0.05 was considered
statistically significant.
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